Scholarlink

<p>Norovirus is a major enteric pathogen with pandemic potential and disproportionately high mortality in low-income countries, particularly among young children. Despite its global health burden, no approved vaccine or specific antiviral therapy is currently available. In this study, we targeted two key viral proteins, viral protein 1 (VP1) and RNA-dependent RNA polymerase (RdRp). The workflow included protein modeling, structural stability assessment, molecular docking, molecular dynamics (MD) simulations, non-covalent interaction (NCI) analysis, protein contact atlas evaluation, and pharmacokinetic (ADME-Tox) profiling. Molecular docking results indicated strong binding affinities of selected phytochemicals—Zingiberol, Cardeonolide, Boeravinone B, β-Elemene, and Fisetin—toward both VP1 and RdRp, with binding energies ranging from − 7.8 to − 9.4&#xa0;kcal/mol. MD simulations further demonstrated the structural stability of protein–ligand complexes, with stable RMSD values (~ 0.3&#xa0;nm for RdRp and 0.3–0.5&#xa0;nm for VP1) and only minor transient fluctuations observed in VP1. RMSF analysis revealed localized flexibility, while radius of gyration, hydrogen bonding patterns, and solvent-accessible surface area collectively confirmed overall conformational stability throughout the simulation period. Complementary protein contact atlas and NCI analyses supported the persistence and robustness of protein–ligand interactions, showing comparable or improved stability relative to reference antivirals ribavirin and nitazoxanide. Additionally, all selected compounds exhibited favorable drug-likeness and acceptable ADME-Tox properties. Collectively, these findings suggest that the identified phytochemicals may serve as promising antiviral candidates against norovirus, although further validation through in vitro and in vivo studies is required.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Structure-based computational screening and molecular dynamics reveal potential inhibitors of Norovirus VP1 and RdRp Proteins: an in-silico study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月24日

查看全文
  • Hasan Huzayfa Rahaman,
  • Nadim Sharif,
  • Al Imran Kafi,
  • Wasifuddin Ahmed,
  • Nazmul Sharif,
  • Fuad M. Alzahrani,
  • Khalaf F. Alsharif,
  • Khalid J. Alzahrani,
  • Shuvra Kanti Dey

摘要

Norovirus is a major enteric pathogen with pandemic potential and disproportionately high mortality in low-income countries, particularly among young children. Despite its global health burden, no approved vaccine or specific antiviral therapy is currently available. In this study, we targeted two key viral proteins, viral protein 1 (VP1) and RNA-dependent RNA polymerase (RdRp). The workflow included protein modeling, structural stability assessment, molecular docking, molecular dynamics (MD) simulations, non-covalent interaction (NCI) analysis, protein contact atlas evaluation, and pharmacokinetic (ADME-Tox) profiling. Molecular docking results indicated strong binding affinities of selected phytochemicals—Zingiberol, Cardeonolide, Boeravinone B, β-Elemene, and Fisetin—toward both VP1 and RdRp, with binding energies ranging from − 7.8 to − 9.4 kcal/mol. MD simulations further demonstrated the structural stability of protein–ligand complexes, with stable RMSD values (~ 0.3 nm for RdRp and 0.3–0.5 nm for VP1) and only minor transient fluctuations observed in VP1. RMSF analysis revealed localized flexibility, while radius of gyration, hydrogen bonding patterns, and solvent-accessible surface area collectively confirmed overall conformational stability throughout the simulation period. Complementary protein contact atlas and NCI analyses supported the persistence and robustness of protein–ligand interactions, showing comparable or improved stability relative to reference antivirals ribavirin and nitazoxanide. Additionally, all selected compounds exhibited favorable drug-likeness and acceptable ADME-Tox properties. Collectively, these findings suggest that the identified phytochemicals may serve as promising antiviral candidates against norovirus, although further validation through in vitro and in vivo studies is required.